Teachers Advisors LLC Boosts Position in Teva Pharmaceutical Industries Limited (TEVA)

Teachers Advisors LLC boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 682,914 shares of the company’s stock after purchasing an additional 40,600 shares during the period. Teachers Advisors LLC owned about 0.07% of Teva Pharmaceutical Industries Limited worth $22,686,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Bronfman E.L. Rothschild L.P. increased its holdings in Teva Pharmaceutical Industries Limited by 7.8% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after purchasing an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC increased its holdings in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after purchasing an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in Teva Pharmaceutical Industries Limited in the 1st quarter valued at approximately $123,000. Sterling Investment Advisors Ltd. increased its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after purchasing an additional 100 shares during the last quarter. Finally, Cutler Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries Limited in the 2nd quarter valued at approximately $133,000. Hedge funds and other institutional investors own 56.76% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.19 on Friday. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $51.51. The stock’s market capitalization is $17.47 billion. The stock has a 50 day moving average of $18.13 and a 200-day moving average of $28.20.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.25 earnings per share. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 1.98%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.36%.

TEVA has been the subject of several research reports. TheStreet downgraded shares of Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a report on Friday, August 25th. ValuEngine downgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Deutsche Bank AG reiterated a “buy” rating and issued a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $32.04 target price for the company in a report on Monday, May 29th. Finally, Credit Suisse Group downgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $25.00 to $13.00 in a research note on Wednesday, August 23rd. Five investment analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $30.91.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/09/24/teachers-advisors-llc-boosts-position-in-teva-pharmaceutical-industries-limited-teva.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply